-
1
المؤلفون: Sandrine Mansard, Philippe Saiag, Hervé Maillard, Amine Denden, Caroline Robert, Laurent Mortier, S. Dalac-Rat, Charlée Nardin, Olivier Dereure, Thierry Lesimple, Laurent Machet, Eve-Marie Neidhardt, Florent Grange, Alexandra Szenik, Caroline Dutriaux, Christophe Bedane, Céleste Lebbé, Jean-Jacques Grob
المساهمون: HAL UVSQ, Équipe, Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay, Hôpital Ambroise Paré [AP-HP], Service de dermatologie, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, Université de Lille, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Léon Bérard [Lyon], Centre Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Université Francois Rabelais [Tours], Service de Dermatologie [CHU Limoges], CHU Limoges, Service de dermatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Novartis Pharma S.A.S., CHU Bordeaux [Bordeaux], Amgen, Bristol-Myers Squibb, BMS, Pfizer, Merck, Novartis, Roche, Sanofi, Meso Scale Diagnostics, MSD, Novartis Pharma, Les Laboratories Pierre Fabre, This work was supported by Novartis Pharma S.A.S. , France., Philippe Saiag has received personal fees from Amgen, Bristol-Myers Squibb, MSD, Merck-Serono, Pfizer, Roche-Genentech, Pierre Fabre, Sanofi and Novartis, he has received non-financial support from Bristol-Myers Squibb, MSD, Roche-Genentech and Novartis, and has received a funding grant from Roche-Genentech., Céléste Lebbe has received honoraria from BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte, has acted as a consultant or has served as a member of an advisory board for BMS, and has received travel grant support from BMS and MSD., Jean-Jacques Grob has received honoraria from BMS, MSD, Merck, Pfizer, Incyte, Novartis, Roche, Amgen and Pierre Fabre, has received travel grant support from BMS, MSD and Roche, and has acted as a consultant and advisor for BMS, MSD, Roche, Novartis, Amgen, Merck, Pierre Fabre, Pfizer and Incyte., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)
المصدر: European Journal of Cancer
European Journal of Cancer, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩
European Journal of Cancer, Elsevier, 2021, 154, pp.57-65. ⟨10.1016/j.ejca.2021.05.031⟩مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, Cancer Research, medicine.medical_specialty, Pyridones, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pyrimidinones, 030204 cardiovascular system & hematology, Regression tree, 03 medical and health sciences, BRAF V600-mutation, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Trametinib, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, medicine, Humans, Prospective Studies, Stage (cooking), Prospective cohort study, education, neoplasms, Melanoma, Aged, Neoplasm Staging, education.field_of_study, Proportional hazards model, business.industry, Dabrafenib, Imidazoles, Middle Aged, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Female, business, Brain metastasis, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7270e6beefeb71081cde6deee2aa0af2Test
https://hal.science/hal-03401780Test -
2
المؤلفون: Caroline Robert, Jacob Schachter, Thierry Lesimple, C. Dutriaux, Dirk Schadendorf, Monique Tan, Axel Hauschild, Georgina V. Long, R. Dummer, Eduard Gasal, Mario Santinami, Kohinoor Dasgupta, James Larkin, Mario Mandalà, Andrew M. Haydon, John M. Kirkwood, Vanna Chiarion Sileni, Laurent Mortier, Victoria Atkinson, Marta Nyakas, Ruth Plummer
المساهمون: University of Zurich
مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, medicine.medical_treatment, Medizin, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Oximes, Medicine, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, Trametinib, Imidazoles, Follow up studies, 10177 Dermatology Clinic, General Medicine, Middle Aged, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Disease-Free Survival, 03 medical and health sciences, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Humans, Stage III melanoma, Protein Kinase Inhibitors, Survival analysis, Aged, Neoplasm Staging, business.industry, Dabrafenib, Survival Analysis, Clinical trial, Mutation, business, Follow-Up Studies
وصف الملف: 848_Dummer_R._et_al._Five-Year_Analysis_of_Adjuvant_Dabrafenib_plus_Trametinib_in_Stage_III_Melanoma_NEJM_2020.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d710d2b0f671e5dafc838391b9965d4aTest
https://www.zora.uzh.ch/id/eprint/190018Test